Turkish Journal of Medical Sciences
Volume 50

Number 2

Article 14

1-1-2020

Tumour budding in preoperative biopsy specimens is a useful
prognostic index foridentifying high-risk patients in early-stage
(pN0) colon cancer
MEHMET ZENGİN
AYDIN ÇİFCİ

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
ZENGİN, MEHMET and ÇİFCİ, AYDIN (2020) "Tumour budding in preoperative biopsy specimens is a
useful prognostic index foridentifying high-risk patients in early-stage (pN0) colon cancer," Turkish Journal
of Medical Sciences: Vol. 50: No. 2, Article 14. https://doi.org/10.3906/sag-1903-142
Available at: https://journals.tubitak.gov.tr/medical/vol50/iss2/14

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Turkish Journal of Medical Sciences

Turk J Med Sci
(2020) 50: 375-385
© TÜBİTAK
doi:10.3906/sag-1903-142

http://journals.tubitak.gov.tr/medical/

Research Article

Tumour budding in preoperative biopsy specimens is a useful prognostic index for
identifying high-risk patients in early-stage (pN0) colon cancer
1,

2

Mehmet ZENGİN *, Aydın ÇİFCİ 
Department of Pathology, Faculty of Medicine, Kırıkkale University, Kırıkkale, Turkey
2
Department of Internal Medical Sciences, Faculty of Medicine, Kırıkkale University, Kırıkkale, Turkey
1

Received: 18.03.2019

Accepted/Published Online: 02.02.2020

Final Version: 09.04.2020

Background/aim: Tumour budding (BD) is considered a valuable prognostic factor in colon cancer (CC), but its use in daily practice is
uncertain. We investigated the prognostic effect of BD using preoperative biopsy specimens in a fairly homogeneous population.
Materials and methods: Eighty-two (pN0) CC patients who underwent surgery after preoperative biopsy between 1997 and 2013 were
included in the study. Model A (using the ‘deeply invasive blocks & hot-spot area & invasive margin) and method 1 (using the ‘20×
objective & immunohistochemistry staining & quantitive counting’) were used as standard methods.
Results: High BD was significantly associated with poor prognostic factors (lymphatic invasion [P = 0.008], perineural invasion [P =
0.041], advanced pT [P = 0.015], invasive margin [P = 0.008], and margin involvement [P = 0.019]). Moreover, correlations between
different BD estimates (r = 0.613–0.696), reproducibility of study (Κappa = 0.68–0.73), and usefulness of cut-off value (area of under
ROC = 0.746 [0.663–0.829]) were well. In univariate analysis, 5-year survival was poor in patients with high BD (relaps-free survival
[RFS]: 71 %, P < 0.001; overall survival [OS]: 73 %, P = 0.004, local recurrence [LR]: 18 %, P = 0.032). Multivariate analyses confirmed
that high BD is an independent worse survival parameter for RFS (Hazard ratio [HR]: 1.53 [1.14–2.80], P = 0.015), OS (HR: 1.44
[1.17–2.75], P = 0.032, and LR (HR: 1.59 [1.05–2.76], P = 0.045).
Conclusion: Our data show that BD provides valuable prognostic information for early-stage (pN0) CC in preoperative biopsy
specimens and that adding BD to current risk classification may contribute to better patient selection.
Key words: Tumour budding, colon cancer, preoperative biopsy, early-stage (pN0)

1. Introduction
Colon cancer (CC) is one of the most common cancers in
the western world and approximately one-third of patients
have early-stage (pN0) disease [1]. Currently, prognosis
estimation in CC is performed by the TNM system, which
combines histopathological and clinical findings [1,2].
The TNM staging system is widely accepted worldwide,
relatively easy, reproducible, and groups patients according
to different progress risks [3]. However, even in this system,
it is difficult to predict the clinical course individually. This
is especially true for early-stage CC patients with a poor
5-year prognosis in approximately 20–30% of patients
[4]. Currently, the routine use of adjuvant chemotherapy
in this patient population remains unclear. Furthermore,
the present risk factors are insufficient to select the ideal
patient for adjuvant therapy in this patient population.
Therefore, additional prognostic markers are needed for
better clinical management [5].

Tumour budding (BD) is defined as the presence
of individually and/or in small groups of tumor cells
at the invasive front [6]. Many authors think that BD
is the first step in epithelial–mesenchymal transition,
lymphovascular invasion, lymph node metastasis, and
distant organ spread [6,7]. Moreover, several studies have
reported that an increase in the number of tumor buds in
CC is associated with poor prognosis [8–14]. In addition,
the International Tumor Budding Consensus Conference
Group recommends that BD be added to high-risk factors
in CC [12]. Therefore, this parameter can be a promising
index for the detection of high-risk patients in early-stage
CCs. However, BD-related studies in the literature show
many differences in methodology and few studies have
investigated only early–stage and preoperative biopsy
[8–14].
In this retrospective cohort, we investigated the
predictive value of BD on tumor progression in early-stage
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(pN0) CC. The distinctive feature of this study was that
it represented a fairly homogeneous population and used a
standard methodology.
2. Materials and methods
This study was designed according to the recommendations
of REMARK [15] and was summarized in Figure 1.
2.1. Ethics statement
This study was approved by the Kırıkkale University Health
Research Ethics Committee. During this research, attention
was paid to comply with the 1964 Helsinki Declaration and
the ethical standards of the institutional/national research
committee. Informed consent was obtained from each
patient and all patients were informed about the content of
the study.
2.2. Data sources
This study was performed at a single university hospital
in Kırıkkale, Turkey. A total of six hundred and fifty-six
patients operated for CC between 1997 and 2013 were
included in the study.
2.3. Patients
Retrospective clinical data of the patients were obtained from
the archival records of Kırıkkale University. Patients with
distant/regional metastasis were not included in this study.
Moreover, patients with multiple tumors, secondary tumors,
and death/recurrence within 1 month were excluded from
the study. Exclusion criteria are summarized as follows:
diagnosed with another cancer before/during primary CC
(n = 9), without tumor block in archives (n = 8), inadequate

tissue for examination (n = 7), stage III and IV disease (n =
530), pN0 disease was not identified in new sections (n=
15), received adjuvant chemoradiotherapy (n = 5). Finally,
the study population consisted of eighty-two patients.
2.4. Samples
Formol-fixed paraffin-embedded tumor specimens
were collected from the archives of Kırıkkale University
Department of Pathology. The number of blocks obtained
was between 3 and 16 per patient (n = 414, mean = 5.4).
Two blocks were selected, one from the preoperative
biopsy material and the other from resection materials. For
immunohistochemical (IHC) study, attention was paid to
the presence of adjacent normal colon tissue and sufficient
tumor tissue in the selected blocks. Four 4-µm thick sections
(n = 328) were cut from each block, two of them stained
with hematoxylin and eosin (H & E), the rest stained
with IHC. Pathological evaluation of the primary tumor
was performed according to the American Joint Cancer
Classification Committee [17]. All sections were evaluated
separately by three experienced pathologists and the final
value was given according to the average of these observers.
2.5. Evaluation of BD
A bud is defined as a small cluster of adenocarcinomas of up
to four cells [16]. The number of tumor buds was visually
noted by conventional microscopy (Nikon Eclipse E600,
Nikon AG Instruments, Switzerland).
Firstly, we scanned all slides using an 10× objective to
see the distribution of the tumor buds. Within the field of
view, an area containing predominantly tumor buds was

Figure 1. Flowchart of the study CC: colon cancer, IHC: Immunohistochemistry HR:
Hazard ratio, OS: Overall survival, RFS: Relapse-free survival
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selected. It was ensured that the selected buds were present
at all borders in this selected image area. Subsequently,
BD was separately noted in 10 high-power fields (HPF)
according to the methods described above (Figure 2).
Finally, all cases were divided into two groups as highdensity and low-density according to the optimal cut-off
value for survival.
To avoid false IHC staining, adenocarcinoma cells
were excluded from the counting unless a clearly defined
blue hematoxylin-stained nucleus was present. In sections
with less than 10 HPF areas (n = 6), all available HPFs were
counted and the final number was given according to the
average of these areas.
2.6. Optimal evaluation method
One of the most important difficulties in achieving
successful results in diagnostic tests is to decide the
optimal evaluation method. Many different methods
have been used in the literature to evaluate BD [8-14].
This study was based on two successful methods, model
A and method 1 [17,18]. Model A recommends using the
hot spot area, deepest invasive block, invasive margin.

Method 1 recommends the use of immunohistochemistry
(IHC) staining, x20 objective, and quantitative counting.
Moreover, the optimal cut-off value for a test in clinical
studies is usually determined by ROC analysis. The best
cut-off value is the value with the lowest false positive
rate and with the highest true positive rate. Since the area
under a ROC (AUC) curve is usually a measure of the
usefulness of a test, a larger area (AUC → 1) means a more
useful test [19].
2.7. Reproducibility of BD
The reproducibility of the study was evaluated by the
following parameters, interobserver agreement and
heterogeneity of the tumor. To evaluate these parameters,
three independent pathologists scored BD without having
the clinical and pathological information. The agreement
between the observers was investigated by calculating the
weighted and simple Kappa value (ĸ). ĸ value is a ratio
of variance indicating interobserver agreement and was
classified by Landis et al. [20] as significant, moderate, and
excellent for values of 0.41–0.60, 0.61–0.80, and 0.81–1,
respectively. Intra- and intertumoral heterogeneity was

Figure 2. Representative examples for BD counting. We have scanned all the slides using an 10× objective to identify areas with the
highest and lowest buds. We chose an area containing mainly tumor buds within the field of view. Tumor buds were present at all borders
of the selected image area. We scored BD (arrows) separately with the two methods mentioned above in 10 high power fields. Finally,
we divided the cases into two groups as low BD (a-b-c) and high BD (d-e-f). BD: Tumour budding.
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determined by the Intra-Class Correlation (ICC) test [21].
ICC was considered to be a ratio of the total variance that
showed the difference between the tumors examined. If
the majority of the variation is due to intertumor variation,
e.g., heterogeneity, ICC will be low (ICC → 0), and if the
majority of the variation is due to intratumor variation,
e.g., biological variation, ICC will be high (ICC → 1).
2.8. Patients follow-up
In this study, survival and recurrence rates were evaluated
for outcome measures. Event endpoint time was calculated
from the day of primary surgery. The follow-up period was
selected as sixteen years (10.5–198.5 months) in all cases.
All events after 60 months of follow-up were recorded as
60 months. Relapse-free survival (RFS) was defined as
the time from primary surgery to death or local/distant
recurrence. Overall survival (OS) was defined as the time
between primary surgery day and death or last contact
day. The clinical, radiological, and pathological relapse of
the disease was called cancer recurrence. This was called
local recurrence (LR) if confined to the previous treatment
site and was called distant recurrence (DR) if spread to a
distant region such as liver and lung.
2.9. Immunohistochemical study
Three 4-µm sections (n =
 246) were cut and placed on
a platinum-coated slide of Dako (Denmark, Glostrup,
K8020). Pretreatment methods were performed using
Dako’s PT link. Using the heat-induced targeting solution
of Dako (EnVision Flex), the retrieval epitope was obtained
at pH 9, 97 ° C for 20 min. The staining was performed
using Dako’s Autostainer link 48. Endogenous peroxidase
activity was blocked by Dako’s peroxidase blocking
reagent (EnVision Flex). The primary antibody was mouse
monoclonal AE1/AE3 (Dako, clone M3515, 1:250) diluted
with the antibody diluent of Dako (EnVision Flex). IHC
staining of mismatch repair proteins was performed
using mouse monoclonal MLH1 (Dako, clone ES05,
1:100) and PMS2 (Dako, clone A16-4, 1:500) antibodies.
These antibodies were incubated for 30 min at room
temperature and the mouse linker of Dako (EnVision
Flex) was used for amplification. The bound antibody
was detected by HRP reaction of Dako (EnVision Flex)
and visualized by DAB reaction of Dako (EnVision Flex).
Meyer hematoxylin (Merck, Germany, Darmstadt) was
used for counterstaining and Pertex (Histolab, Sweden,
Gothenburg) was used to cover the slides.
2.10. Statistical evaluation
Percentage and frequency were used for categorical
variables, and range, mean, and standard deviation (SD)
were used for continuous variables. Chi-squared test was
used for the relationship between clinicopathological
features and BD. While analyzing the continuous data, the
Wilcoxon signed-level test was used to examine whether
there was a difference between these data and Spearman
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correlation analysis was used to examine whether there
was a correlation. As described above, the optimal cut-off
value associated with survival was evaluated by the ROC
analysis, the heterogeneity of tumors was examined by the
ICC test, and the interobserver agreement was investigated
by the ĸ test. The difference between univariate survival
groups was evaluated by Log-rank test and survival curves
were presented by Kaplan-Meier method. Multivariate
survival groups were evaluated by Cox-regression model
with a 95% confidence interval (CI) and a hazard ratio
(HR) of 1.0. All tests were two-sided and P-values less than
0.05 were considered significant. SPSS 21.0 (IBM Institute,
North Castle, USA) was used in the analyses.
3. Results
3.1. Patients
The mean of age and size were 72.48 ± 8.17 years (range:
35–87 years) and 4.67 ± 1.85 cm (range: 2–9 cm),
respectively. Thirty-three (40.2 %) of the patients were
female and 49 (59.8 %) were male. Thirty-two (39.0 %) of
the cases were pT1, 50 (61.0 %) were pT2; 28 (34.1 %) of
the cases were low/moderately differentiated, and 54 (65.9
%) were poorly differentiated.
3.2. Scoring of BD
In BD screening, the distribution of buds was not
homogeneous on the slides. One independent section
with a good bud homogeneity level was selected from
preoperative and postoperative biopsy samples. The mean
of BD numbers was 7.37 ± 4.84 for the biopsy and was
7.98 ± 5.24 for the resection, respectively. Representative
images for BD counting were shown in Figure 2.
3.3. Optimal evaluation method
BD was scored separately using model A and method 1 as
described above. When the results were examined, there
was a good relationship between BD (biopsy) and poor
prognostic parameters (lymphatic invasion [P = 0.008],
perineural invasion [P = 0.041], advanced pT [P = 0.012],
invasive margin [P = 0.008] and margin involvement [P =
0.019]) (Table 1). Moreover, when continuous data were
analyzed, the correlation between BD (biopsy) estimates
was quite high (R = 0.696, P < 0.001) and the difference
was quite low (R = 0.321, P < 0.001) (Table 2). In addition,
the cut-off value for BD (biopsy) was useful (ROC: 10.37;
AUC = 0.746 [0.663-0.829]) (Figure 3). For convenience,
this value was considered 10 and all samples were divided
into two groups using this value.
3.4. Reproducibility of BD
The analysis was performed for both categorical and
continuous variables and similar results were found.
Therefore, only the best results were given here as an
example. The reproducibility of the study was evaluated as
follows:
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Table 1. Relationship between BD and prognostic factors.
Biopsy
Low BD

Resection
High BD

P-value

Low BD

High BD

0.432
Age

<72

15 (53)

24 (44)

≥72

13 (47)

30 (56)

0.135
15 (60)

24 (42)

10 (40)

33 (58)

0.119
Size

0.067

<4 cm

17 (60)

23 (42)

16 (64)

24 (42)

≥4 cm

11 (40)

31 (58)

9 (36)

33 (58)

Female

9 (32)

24 (44)

8 (32)

25 (43)

Male

19 (68)

30 (56)

17 (68)

32 (57)

0.281
Gender

0.313

0.008

0.014*

*

Lymphatic
invasion

No

19 (67)

20 (37)

Yes

9 (33)

34 (63)

17 (68)

22 (38)

8 (32)

35 (62)

0.041

0.022*

*

Perineural
invasion

No

17 (60)

20 (37)

16 (64)

21 (36)

Yes

11 (40)

34 (63)

9 (36)

36 (64)

0.759
LIR

No

15 (53)

27 (50)

Yes

13 (47)

27 (50)

0.925
13 (52)

29 (51)

12 (48)

28 (49)

0.015*
pT-stage

pT1

16 (57)

16 (29)

pT2

12 (43)

38 (71)

0.009*
15 (60)

17 (29)

10 (40)

40 (71)

0.008*

0.002*

Invasive
margin

No

20 (71)

22 (40)

19 (76)

23 (40)

Yes

8 (29)

32 (60)

6 (24)

34 (60)

Margin
involvement

No

19 (67)

22 (40)

18 (72)

23 (40)

Yes

9 (33)

32 (60)

7 (28)

34 (60)

MSI Status

MMR-P

16 (57)

24 (44)

14 (56)

26 (45)

MMR-D

12 (43)

30 (56)

11 (44)

31 (55)

0.019*

0.008*

0.275

0.386

0.782
Grade

Tumour
necrosis

P-value

0.459

Low-grade

9 (50)

19 (44)

10 (40)

18 (31)

Moderate / High-grade

19 (50)

35 (56)

15 (60)

39 (69)

0.351

0.258

No

16 (57)

25 (46)

13 (52)

22 (38)

Yes

12 (43)

29 (54)

12 (48)

35 (62)

*. The significance level for the P-value is 0.05. Significant results are shown in italics. BD: Tumour budding, LIR: Local inflammatory
response, MSI: Microsatellite instability, MMR-P: Mismatch repair proteins proficiency, MMR-D: Mismatch repair proteins deficiency,
pT: Pathologic tumour stage
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Table 2. Analysis of continuous variables for BD.
N

BD (Biopsy)

BD (Resection)

BD (A & B)

82

0.696 (S), P = 0.321 (W)

0.729 (S), P = 0.312 (W)

BD (A & C)

82

0.642 (S), P = 0.435 (W)

0.686 (S), P = 0.438 (W)

BD (B & C)

82

0.613 (S), P = 0.473 (W)

0.617 (S), P = 0.470 (W)

BD: Tumour budding, S: Spearsman correlation analysis, W: Wilcoxon Signed Rank test, A: First
observer, B: Second observer, C: Third observer, N: Number

Figure 3. Optimal cut-off value for BD. AUC analyzed by manual
methods. BD: Tumour budding, ROC: Receiver Operating
Characteristic, AUC: Areas under the ROC curves.

3.4.1. Agreement of observers
In general, the interobserver agreement ranged from
moderate to significant and was clinically useful (ĸ = 0.68–
0.73). We also found that the interobserver agreement
for BD (biopsy) was slightly lower than BD (resection)
(Table 3). This was a finding we expected. Because a smaller
area was examined in the biopsy material compared to the
resection material.
3.4.2. Heterogeneity of tumor
In general, the majority of the variation was due to
biological differences between tumors. For example, an
ICC count of 0.677 means that 67.7% of the total variance is
due to intertumor heterogeneity. Moreover, ICC values of

BD (biopsy) were slightly lower than BD (resection). This
can be explained as follows. As more areas of the tumor
were examined, heterogeneity was higher in resection
materials (Table 3).
3.5. Follow-up events
Twenty-seven patients died (high BD, n = 25; low BD, n =
2) during the 16-year follow-up and twenty-nine patients
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recurred (high BD, n = 26; low BD, n = 3). Moreover,
twelve patients had LR (high BD, n = 10; low BD, n = 2)
and ten patients had DR (high BD, n = 8; low BD, n = 2).
Five-year RFS and OS ratios were 71–73% in high BD
(biopsy) patients and 95–95% in low BD (biopsy) patients,
respectively. Moreover, five-year LR and DR ratios were
18–16% in high BD (biopsy) and 6–7% in low BD (biopsy),
respectively (Table 4).
3.6. Univariable survival analyses
In univariate analysis, significant differences were observed
between BD (biopsy) and survival groups for RFS (P =
0.001), OS (P = 0.004), and LR (P = 0.032). Moreover, pTstage and margin involvement were significantly associated
with poor RFS and margin involvement was significantly
associated with poor OS (Table 4, Figure 4).
3.7. Multivariable survival analyses
In multivariate analysis, high BD (biopsy) was an
independent worse prognostic parameter for RFS (HR =
1.53 [1.14–2.80], P = 0.015), OS (HR = 1.44 [1.17–2.75],
P = 0.032 ), and LR (HR = 1.59 [1.05–2.76], P = 0.045).
Margin involvement was another parameter that was
significantly associated with poor RFS (Table 5).
4. Discussion
In this study, we investigated the prognostic effect of BD
in early-stage (pN0) CC patients who underwent surgery
after the preoperative biopsy. Our results show that the
evaluation of this factor in preoperative biopsies is useful
in predicting prognosis. We also found that the use of
model A and method 1 is beneficial in the evaluation of
BD.
For preoperative biopsy specimens, BD has been shown
to be a poor prognostic factor. For example, Morodomi et al.
[22] showed that the budding number was associated with
lymph node metastasis in rectal cancer patients. Giger et
al. [23] examined preoperative biopsies and corresponding
resection specimens in colorectal cancer patients and
confirmed these findings. Rogers et al. [24] demonstrated
the predictive power of BD for nodal metastasis in
rectal cancer patients treated with neoadjuvant therapy.
However, these studies are quite different in terms of both
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Table 3. Reproducibility of study.
N

ICC- Categorical (95 % CI)

ĸ values

BD (A & B) (Resection)

82

0.677 (0.584-0.803)

0.73

BD (A & C) (Biopsy)

85

0.654 (0.532-0.785)

0.71

BD (B & C) (Resection)

82

0.638 (0.513-0.771)

0.68

BD: Tumour budding, ĸ: Kappa values, ICC: Intra-class correlation coefficient, CI: Confidence
interval, A: First observer, B: Second observer, C: Third observer, N: Number

assessment methods and study populations. In this study,
we found that BD is an independent prognostic factor for
poor RFS, OS, and LR. Moreover, the population consisted
of only early-stage patients (pN0) and only CC patients. In
addition, to increase the homogeneity of the population,
patients treated with adjuvant chemotherapy and known
to have secondary malignancy were excluded. In other
words, in contrast to other studies, we selected our patient
population to be highly homogeneous.
For resection specimens, many early-stage CC studies
in the literature have shown that high BD is associated with
worse prognosis [25–30]. Moreover, a few studies have
found no prognostic significance [31]. The main reason
why this prognostic marker cannot be fully integrated into
pathology reports is the lack of a standardized evaluation
system [25–30]. A different feature of this study is that it
provides a standard approach to pathological evaluation.
That is, two standard evaluation methods were used in
this study. Briefly, histopathological evaluations can be
divided intrabiopsy evaluation (section, area and focus)
and extrabiopsy evaluation (staining, magnification,
and counting). Model A [17] was used for intrabiopsy
evaluation and method 1 [18] was used for extrabiopsy
evaluation. And both of these methods yielded successful
results. Therefore, unlike other studies, our study was quite
standard in terms of methodology.
There are different findings regarding the ratio and
mean value of BD in publications. In general, high BD
rates of 19% to 45% [8,32] and mean bud values of 7.11
to 8.05 [25,32] have been reported. For example, Koelzer
et al. [25] reported a high BD rate of 30% and an average
of 7.11 buds. We found a high BD rate of 65% and an
average of 7.37 buds. These differences can be explained by
the heterogeneity of tumors and the variety of evaluation
methods. In the following paragraph, we will discuss the
heterogeneity of BD. As for the differences in evaluation
methods, we used two successful standard methods
described above in this study. Moreover, we calculated
BD in 10 HPFs, and this method can change the average
number. In addition, we have only counted BD cells with
a clearly identifiable blue nucleus, so the results may
have changed due to this counting rule. As a result, we

believe that the differences arise from the variability of
the methods, and we recommend the above-mentioned
standard counting technique for future studies.
In the literature, the issue of heterogeneity of CC
is considered a serious problem [33,34]. For example,
Mesker et al. [33] reported that the deeply infiltrated tumor
sections in the bowel wall had the lowest tumor cells and
recommended the use of the highest pT-stage histological
section in the evaluation of the primary tumor. In this
study, we used the deeply infiltrated tumor section and we
found that the heterogeneity of BD was significantly higher
among different tumors. We believe that this problem can
be overcome by the two standard methods mentioned
above. Moreover, it is understood that different technical
approaches can provide a higher degree of precision and
accuracy. In future studies, the heterogeneity of CC needs
to be further investigated methodologically.
The current consensus in the literature suggests that
BD should be evaluated using H & E [11,12]. However,
there are also studies reporting that evaluation of BD with
IHC increases detection rates and interobserver agreement
[25,35]. However, it is not clear whether the evaluation
by IHC is prognostically different from the evaluation by
H & E. In our study, although the evaluation was mainly
made with IHC stained sections, we also evaluated the H
& E stained sections at some stages of our study. One of
the challenges of using IHC was as that some cell types
other than malignant adenocarcinoma cells also showed
reactivity with IHC, e.g., cells of vascular neoangiogenesis.
One of the difficulties in using H & E was that many
different structures had a budding-like appearance, e.g.,
disintegration of tumor glands secondary to intense
inflammation. As a result, more comprehensive studies are
needed for standardization of staining methods.
There are many important aspects of our research.
A good parameter recently discussed in numerous
large studies was presented. Our population was quite
homogeneous because it was based on a well-characterized
cohort of early-stage (pN0) CC patients without adjuvant
therapy. Two well-standardized pathological methods
were used in this study. And all stages of this study were
designed according to the REMARK guidelines.
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Table 4. Univariate survival analysis of BD.

Age

OS

RFS

5-year (%) P-value

5-year (%)

0.736
< 72
≥ 72

88
82

< 4 cm
≥ 4 cm

90
80

Gender

Female
Male

87
83

No
Yes

91
78

No
Yes

92
77

LIR

No
Yes

87
84

pT-stage

pT1
pT2

93
75

No
Yes

91
78

Lymphatic
İnvasion
Perineural
İnvasion

Invasive
margin
Margin
involvement
MSI Status

Tumour
necrosis
BD
(Biopsy)
BD
(Resection)

5-year (%)

0.644

91
80
0.878

0.835

0.353

0.718

94
72
0.274

0.844

0.199

0.156

0.042*

0.286
9
16

0.465
12
15

0.014*
95
71

0.954
16
16

8
16

80
84

0.467
12
16

15
16
0.033*

0.068

0.374
11
15

12
15

87
83

0.962
15
15

0.212

0.147

0.819

0.512
13
15

10
15

92
77

0.744

0.461

0.182

0.779
14
15

0.130

94
74

MMR -P
MMR -D

86
83

Low grade
Moderate /
High grade

85

85

15

14

84

84

16

16

No
Yes

86
85

Low
High

95
73

0.722
86
85

0.831

0.714

0.458

0.001*

0.572
13
16

0.032*
6
18

<0.001*
96
70

0.945
15
15

13
15

96
71
0.001*

96
72

0.719

0.461
88
84

0.004*

11
16

16
14
0.894

0.524

Low
High

11
16

0.176

No
Yes

0.866

0.065
7
16

0.018*
5
18

P-Value

14
16

15
14

92
78

5-year (%)

0.686

0.792

0.229

P-value

12
16

88
82
0.257

DR

14
16
0.384

0.945
Grade

P-value

89
81
0.415

Size

LR

0.042*
6
17

*. The significance level for the P-value is 0.05. Significant results were in italics. Abbreviations: BD: Tumour budding, pT: Pathologic
tumour stage, LIR: Local inflammatory response, MSI: Microsatellite instability, MMR-P: Mismatch repair proteins proficiency, MMR-D:
Mismatch repair proteins deficiency, OS: Overall survival, RFS: Relapse-free survival, LR: Local recurrence, DR: Distant recurrence
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Figure 4. Survival and recurrence curves for BD. Kaplan–Meier survival curves were used for overall survival (a), relapse-free survival
(b), local recurrence (c), and distant recurrence (d). The significance level for the P-value is 0.05

Table 5. Multivariate survival analysis of the four parameters.

pT-stage

Overall survival
(n = 82) (%)

Relaps-free survival
(n = 82) (%)

Local recurrence
(n = 82) (%)

Distant recurrence
(n = 82) (%)

HR
(95 % CI)

HR
(95 % CI)

HR
(95 %CI)

P value

HR
(95 % CI)

P value

1

-

1

-

0.519

NC

0.897

pT1

1

pT2

2.57
(0.65-10.7)

No

P value
-

P value
-

1

0.356

1.86
(0.55-11.1)

0.284

3.81
(0.50-7.83)

1

-

1

-

1

-

1

-

Yes

2.35
(0.57-9.33)

0.212

1.63
(1.19-2.91)

0.041*

7.60
(0.44-13.5)

0.453

9.30
(0.39-17.4)

0.594

BD

<10

1

-

1

1

-

1

-

(Biopsy)

≥10

1.44
(1.17-2.75)

0.032*

1.53
(1.14-2.80)

1.59
(1.05-2.76)

0.045*

1.67
(0.91-3.12)

0.098

BD

<10

-

1

1

-

1

-

(Resection)

≥10

0.013*

1.49
(1.17-2.64)

1.57
(1.07-2.54)

0.033*

1.65
(0.93-3.24)

0.056

Margin
involvement

1.42
(1.23-2.89)

0.015*
0.003*

*. The significance level for the P-value is 0.05. Significant results in italics.
BD: Tumour budding, pT: Pathologic tumour stage, CI: Confidence interval, HR: Hazard ratio, OS: Overall survival, RFS: Relapse-free
survival, LR: Local recurrence, DR: Distant recurrence, NC: Not calculable
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Our study had some limitations. First, it was impossible
to overcome the sampling difference since the tissue
under investigation was sampled for diagnosis previously.
We have evaluated many different areas of a tumor, but
we know that this was only a small part of an entire
tumor. Recurrence and death data were obtained from
archive records and individual patient records were not
evaluated. Moreover, since patients were treated according
to protocols before 2013, there may be differences with
current treatment protocols.
Our results confirm the predictive value of BD in CC
patients. At least hypothetically, BD can predict the need

for chemo-radiotherapy in early-stage (pN0) patients
in preoperative biopsy specimens. We also recommend
using model A and method 1 for more successful results
in future studies.
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